Table 1

Baseline characteristics

Lispro, N = 337URLi, N = 336Overall, N = 673
Age (years), mean ± SD61.0 ± 9.260.2 ± 9.460.6 ± 9.3
Women/men, %48.1/51.945.2/54.846.7/53.3
Race, n (%)
 American Indian or Alaska Native3 (0.9)1 (0.3)4 (0.6)
 Asian81 (24.0)83 (24.7)164 (24.4)
 Black or African American16 (4.7)14 (4.2)30 (4.5)
 Multiple6 (1.8)5 (1.5)11 (1.6)
 Native Hawaiian or other Pacific Islander1 (0.3)0 (0.0)1 (0.1)
 White229 (68.0)233 (69.3)462 (68.6)
Hispanic or Latino, n (%)78 (23.1)79 (23.5)157 (23.3)
Weight (kg), mean ± SD90.0 ± 20.089.8 ± 20.589.9 ± 20.2
BMI (kg/m2), mean ± SD32.4 ± 5.832.1 ± 5.732.3 ± 5.7
Duration of diabetes (years), mean ± SD16.6 ± 7.916.4 ± 7.816.5 ± 7.8
Number of prestudy bolus injections, n (%)
 <3/day85 (25.2)83 (24.7)168 (25.0)
 ≥3/day252 (74.8)253 (75.3)505 (75.0)
Basal insulin during study, n (%)
 Insulin glargine257 (76.3)260 (77.4)517 (76.8)
 Insulin degludec80 (23.7)76 (22.6)156 (23.2)
OAM use during study, n (%)
 Metformin231 (68.5)244 (72.6)475 (70.6)
 SGLT2 inhibitor54 (16.0)65 (19.3)119 (17.7)
HbA1c at study entry, mean ± SD
 %8.30 ± 0.758.30 ± 0.798.30 ± 0.77
 mmol/mol67.2 ± 8.367.2 ± 8.667.2 ± 8.4
HbA1c at randomization, mean ± SD
 %7.31 ± 0.727.27 ± 0.687.29 ± 0.70
 mmol/mol56.4 ± 7.956.0 ± 7.556.2 ± 7.7
  • SGLT2, sodium–glucose cotransporter 2.